Clinical Trial Detail

NCT ID NCT02174172
Title A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

renal cell carcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

lung non-small cell carcinoma

melanoma

Therapies

Atezolizumab + Bevacizumab + Peg-interferon alfa-2a

Atezolizumab + Interferon alpha-2b

Atezolizumab + Peg-interferon alfa-2a

Atezolizumab + Ipilimumab

Atezolizumab + Obinutuzumab

Age Groups: adult

No variant requirements are available.